18Fluorodeoxyglucose PET in schizophrenia

Psychiatry Res. 1985 Dec;16(4):317-29. doi: 10.1016/0165-1781(85)90123-4.

Abstract

Six chronic schizophrenic patients and six age-matched controls were studied with 18fluorodeoxyglucose (18FDG) positron emission tomography (PET). All patients were scanned when they had been free of medication for at least 2 weeks. Comparisons were made between the groups on regional ratios of cortical 18FDG, with manual and automated measures. Only one of eight regions, the right temporal cortical region, showed a significant group difference, and this effect was not significant when adjustment was made for multiple comparisons. Secondary analyses suggest that ventricular enlargement and age may be associated with a relatively "hypofrontal" pattern of 18FDG.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Arousal / physiology*
  • Attention / physiology
  • Blood Glucose / metabolism*
  • Cerebral Cortex / physiopathology*
  • Chronic Disease
  • Deoxyglucose / analogs & derivatives
  • Fluorodeoxyglucose F18
  • Humans
  • Male
  • Middle Aged
  • Pitch Discrimination / physiology
  • Schizophrenia / physiopathology*
  • Tomography, Emission-Computed*

Substances

  • Blood Glucose
  • Fluorodeoxyglucose F18
  • Deoxyglucose